BACKGROUND: The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) have been implicated as therapeutic targets for head and neck squamous cell carcinoma (HNSCC). Vandetanib is a small-molecule tyrosine kinase inhibitor (TKI) with dual specificity for EGFR and VEGFR. Here we characterize the phenotypic and biochemical effects of vandetanib on various HNSCC cell lines. METHODS: In vitro models were used for studying tumor cell viability, invasion, and signaling as well as in vivo xenograft models. RESULTS: Treatment with vandetanib reduced viability, invasion, and tumor growth of HNSCC cell lines. Phosphorylation levels of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) were reduced in vandetanib-treated HNSCC cells. Additionally, vandetanib abrogates EGF-induced STAT3 activity and STAT3 target gene expression. CONCLUSIONS: We demonstrated that vandetanib inhibits the growth of head and neck cancer cell lines. The antitumor effects of vandetanib appear to be exerted via the EGFR inhibitory effect of the compound.
BACKGROUND: The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) have been implicated as therapeutic targets for head and neck squamous cell carcinoma (HNSCC). Vandetanib is a small-molecule tyrosine kinase inhibitor (TKI) with dual specificity for EGFR and VEGFR. Here we characterize the phenotypic and biochemical effects of vandetanib on various HNSCC cell lines. METHODS: In vitro models were used for studying tumor cell viability, invasion, and signaling as well as in vivo xenograft models. RESULTS: Treatment with vandetanib reduced viability, invasion, and tumor growth of HNSCC cell lines. Phosphorylation levels of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) were reduced in vandetanib-treated HNSCC cells. Additionally, vandetanib abrogates EGF-induced STAT3 activity and STAT3 target gene expression. CONCLUSIONS: We demonstrated that vandetanib inhibits the growth of head and neck cancer cell lines. The antitumor effects of vandetanib appear to be exerted via the EGFR inhibitory effect of the compound.
Authors: Terrance G Johns; Rodney B Luwor; Carmel Murone; Francesca Walker; Janet Weinstock; Angela A Vitali; Rushika M Perera; Achim A Jungbluth; Elisabeth Stockert; Lloyd J Old; Edouard C Nice; Antony W Burgess; Andrew M Scott Journal: Proc Natl Acad Sci U S A Date: 2003-12-15 Impact factor: 11.205
Authors: Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis Journal: Clin Cancer Res Date: 2008-07-01 Impact factor: 12.531
Authors: Orhan G Yigitbasi; Maher N Younes; Dao Doan; Samar A Jasser; Bradley A Schiff; Corazon D Bucana; Benjamin N Bekele; Isaiah J Fidler; Jeffrey N Myers Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Guilian Niu; Kenneth L Wright; Mei Huang; Lanxi Song; Eric Haura; James Turkson; Shumin Zhang; Tianhong Wang; Dominic Sinibaldi; Domenico Coppola; Richard Heller; Lee M Ellis; James Karras; Jacqueline Bromberg; Drew Pardoll; Richard Jove; Hua Yu Journal: Oncogene Date: 2002-03-27 Impact factor: 9.867
Authors: Eliezer M Van Allen; Vivian W Y Lui; Ann Marie Egloff; Eva M Goetz; Hua Li; Jonas T Johnson; Umamaheswar Duvvuri; Julie E Bauman; Nicolas Stransky; Yan Zeng; Breean R Gilbert; Kelsey P Pendleton; Lin Wang; Simion Chiosea; Carrie Sougnez; Nikhil Wagle; Fan Zhang; Yu Du; David Close; Paul A Johnston; Aaron McKenna; Scott L Carter; Todd R Golub; Gad Getz; Gordon B Mills; Levi A Garraway; Jennifer R Grandis Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Rogerio B Craveiro; Michael Ehrhardt; Julia Velz; Martin Olschewski; Barbara Goetz; Torsten Pietsch; Dagmar Dilloo Journal: Oncotarget Date: 2017-07-18